Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
2774- Bos,    Boswellia ovalifoliolata abrogates ROS mediated NF-κB activation, causes apoptosis and chemosensitization in Triple Negative Breast Cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-453
ChemoSen↑, Casp3↑, ROS↓, NF-kB↓,
5675- Bos,    Modulation of Pgp function by boswellic acids
- in-vitro, Nor, NA
*P-gp↑,
1169- Bos,    Boswellic Acid Inhibits Growth and Metastasis of Human Colorectal Cancer in Orthotopic Mouse Model By Downregulating Inflammatory, Proliferative, Invasive, and Angiogenic Biomarkers
- in-vivo, CRC, NA
TumCG↓, TumVol↓, Weight∅, ascitic↓, TumMeta↓, Ki-67↓, CD31↓, NF-kB↓, COX2↓, Bcl-2↓, Bcl-xL↓, IAP1↓, survivin↓, cycD1/CCND1↓, ICAM-1↓, MMP9↓, CXCR4↓, VEGF↓,
1248- Bos,    The anti-proliferative effects of a frankincense extract in a window of opportunity phase ia clinical trial for patients with breast cancer
- Trial, BC, NA
TumCP↓,
1185- Bos,    The journey of boswellic acids from synthesis to pharmacological activities
- Review, NA, NA
BAX↑, NF-kB↓, cl‑PARP↑, Casp3↑, Casp8↑,
1417- Bos,    Potential complementary and/or synergistic effects of curcumin and boswellic acids for management of osteoarthritis
- Review, Arthritis, NA
5LO↓, COX2↓, PGE2↓,
1427- Bos,    Acetyl-keto-β-boswellic acid inhibits cellular proliferation through a p21-dependent pathway in colon cancer cells
- in-vitro, CRC, HT-29 - in-vitro, CRC, HCT116 - in-vitro, CRC, LS174T
TumCG↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, p‑RB1↓, P21↑,
1419- Bos,    Enhanced Bioavailability of Boswellic Acid by Piper longum: A Computational and Pharmacokinetic Study
- in-vivo, Nor, NA
*BioAv↑,
1420- Bos,    Acetyl-11-keto-β-boswellic acid inhibits proliferation and induces apoptosis of gastric cancer cells through the phosphatase and tensin homolog /Akt/ cyclooxygenase-2 signaling pathway
- vitro+vivo, GC, BGC-823
TumCP↓, TumCG↓, PTEN↑, BAX↑, Bcl-2↓, p‑Akt↓, COX2↓,
1421- Bos,    Coupling of boswellic acid-induced Ca2+ mobilisation and MAPK activation to lipid metabolism and peroxide formation in human leucocytes
- in-vitro, AML, HL-60 - in-vitro, Nor, NA
ROS↑, NADPH↝, 5LO↓, Ca+2↑, p38↑, p42↑,
1422- Bos,    Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family
- in-vitro, CRC, NA - in-vivo, NA, NA
5LO↓, TumCG↓, Let-7↑, miR-200b↑, NF-kB↓, cMyc↓, cycD1/CCND1↓, MMP9↓, CXCR4↓, VEGF↓, Bcl-xL↓, survivin↓, IAP1↓, XIAP↓, TumCG↓, CDK6↓, Vim↓, E-cadherin↑,
1423- Bos,    Acetyl-11-keto-β-Boswellic Acid Suppresses Invasion of Pancreatic Cancer Cells Through The Downregulation of CXCR4 Chemokine Receptor Expression
- in-vitro, Melanoma, U266 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, SkBr3 - in-vitro, PC, PANC1
CXCR4↓, TumCI↓, HER2/EBBR2↓, NF-kB↓,
1424- Bos,    Boswellia sacra essential oil induces tumor cell-specific apoptosis and suppresses tumor aggressiveness in cultured human breast cancer cells
- in-vitro, BC, T47D - in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
tumCV↓, Apoptosis↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑,
1425- Bos,    Protective Effect of Boswellic Acids against Doxorubicin-Induced Hepatotoxicity: Impact on Nrf2/HO-1 Defense Pathway
- in-vivo, Nor, NA
*ChemoSen↑, *NRF2↑, *HO-1↑, *ROS↓, *lipid-P↓, *DNAdam↓,
1426- Bos,  CUR,  Chemo,    Novel evidence for curcumin and boswellic acid induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer
- in-vivo, CRC, NA - in-vitro, CRC, HCT116 - in-vitro, CRC, RKO - in-vitro, CRC, SW480 - in-vitro, RCC, SW-620 - in-vitro, RCC, HT-29 - in-vitro, CRC, Caco-2
miR-34a↑, miR-27a-3p↓, TumCG↓, BAX↑, Bcl-2↓, PARP1↓, TumCCA↑, Apoptosis↑, cMyc↓, CDK4↓, CDK6↓, cycD1/CCND1↓, ChemoSen↑, miR-34a↑, miR-27a-3p↓,
1416- Bos,    Anti-cancer properties of boswellic acids: mechanism of action as anti-cancerous agent
- Review, NA, NA
5LO↓, TumCCA↑, LC3B↓, PI3K↓, Akt↓, Glycolysis↓, AMPK↑, mTOR↓, Let-7↑, COX2↓, VEGF↓, CXCR4↓, MMP2↓, MMP9↓, HIF-1↓, angioG↓, TumCP↓, TumCMig↓, NF-kB↓,
2024- Bos,    Antiproliferative and cell cycle arrest potentials of 3-O-acetyl-11-keto-β-boswellic acid against MCF-7 cells in vitro
- in-vitro, BC, MCF7 - in-vitro, Nor, MCF10
MMP↓, Cyt‑c↑, ROS↑, Casp8↑, Casp9↑, AntiTum↑, selectivity↑, TumCCA↑,
1451- Bos,    Phytochemical Analysis and Anti-cancer Investigation of Boswellia serrata Bioactive Constituents In Vitro
- in-vitro, CRC, HepG2 - in-vitro, CRC, HCT116
eff↑,
1448- Bos,    A triterpenediol from Boswellia serrata induces apoptosis through both the intrinsic and extrinsic apoptotic pathways in human leukemia HL-60 cells
- in-vitro, AML, HL-60
TumCP↓, Apoptosis↑, ROS↑, NO↑, cl‑Bcl-2↑, BAX↑, MMP↓, Cyt‑c↑, AIF↑, Diablo↑, survivin↓, ICAD↓, Casp↑, cl‑PARP↑, DR4↑, TNFR 1↑,
1447- Bos,    Boswellia carterii n-hexane extract suppresses breast cancer growth via induction of ferroptosis by downregulated GPX4 and upregulated transferrin
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7 - in-vivo, BC, 4T1 - in-vitro, Nor, MCF10
tumCV↓, AntiCan↑, *toxicity↓, Ferroptosis↑, i-Iron↑, GPx4↓, ROS↑, lipid-P↑, Tf↑, TumCG↓,
1449- Bos,  Chemo,    Anti-proliferative, Pro-apoptotic, and Chemosensitizing Potential of 3-Acetyl-11-keto-β-boswellic Acid (AKBA) Against Prostate Cancer Cells
- in-vitro, Pca, PC3
TumCP↓, ChemoSen↑, MMP↝, ROS↝, Apoptosis↑,
1450- Bos,  Cisplatin,    3-Acetyl-11-keto-β-boswellic acid (AKBA) induced antiproliferative effect by suppressing Notch signaling pathway and synergistic interaction with cisplatin against prostate cancer cells
- in-vitro, Pca, DU145
ROS↑, MMP↓, Casp↑, Apoptosis↑, Bax:Bcl2↑, TumCCA?, cycD1/CCND1↓, CDK4↓, P21↑, p27↑, NOTCH↓, ChemoSen↑,
5648- BP,    Combined photothermal and sonodynamic therapy using a 2D black phosphorus nanosheets loaded coating for efficient bacterial inhibition and bone-implant integration
- in-vivo, Nor, NA
sonoS↑, PhotoS↑,
5647- BP,    Black Phosphorus Quantum Dots Enhance the Radiosensitivity of Human Renal Cell Carcinoma Cells through Inhibition of DNA-PKcs Kinase
- in-vitro, RCC, NA
RadioS↑, DNAdam↑,
5646- BP,    Black Phosphorus, an Emerging Versatile Nanoplatform for Cancer Immunotherapy
- Review, Var, NA
ROS↑, Imm↑, PhotoS↑,
5645- BP,    Accumulation, distribution, and toxicity of black phosphorus nanomaterials across biological systems: a critical review
- Review, Var, NA
ROS↑,
5695- BRU,    Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
- in-vitro, Lung, A549
NRF2↓, ChemoSen↑, Apoptosis↑, TumCP↓, TumCG↓, MRP1/ABCC1↓, GSH↓, cMyc↓,
5691- BRU,    Brusatol Inhibits Proliferation, Migration, and Invasion of Nonsmall Cell Lung Cancer PC-9 Cells
- in-vitro, Lung, PC9 - in-vitro, Lung, H1975
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, EGFR↓, β-catenin/ZEB1↓, Akt↓, STAT3↓, TumMeta↓, ChemoSen↑, NRF2↓, Akt↓, mTOR↓,
5693- BRU,    Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2
- in-vivo, HCC, NA
NRF2↓, eff↑, p‑MAPK↑, p‑Akt↑, p‑ERK↑, p‑JNK↑,
5694- BRU,    Brusatol overcomes chemoresistance through inhibition of protein translation
- in-vitro, Lung, A549
NRF2↓, P53↓, P21↓,
5696- BRU,    The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer
- in-vitro, CRC, HCT116
NRF2↓, tumCV↓, ChemoSen↑,
5697- BRU,    Brusatol, a Nrf2 Inhibitor Targets STAT3 Signaling Cascade in Head and Neck Squamous Cell Carcinoma
- in-vitro, HNSCC, NA
NRF2↓, STAT3↓, proCasp3↑, cl‑PARP↑, Bcl-2↓, Bcl-xL↓, survivin↓, Hif1a↓, cMyc↓, JNK↑, MAPK↑, tumCV↓, ROS∅,
5698- BRU,    Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma
- in-vitro, HCC, NA
TumCMig↓, EMT↓, STAT3↓, E-cadherin↑, NRF2↓, ChemoSen↑, RadioS↑, DNAdam↑, TumCMig↓, TumCI↓, toxicity↓,
5699- BRU,  BJ,    Identification of the Brucea javanica Constituent Brusatol as a EGFR-Tyrosine Kinase Inhibitor in a Cell-Free Assay
- in-vitro, Lung, A549
EGFR↓, ChemoSen↑, NRF2↓, STAT3↓, PI3K↓, Akt↓, mTOR↓, ROCK1↓, Hif1a↓,
5700- BRU,    Brusatol modulates the Nrf2/GCLC pathway to enhance ferroptosis in the treatment of oral squamous cell carcinoma
- in-vitro, Oral, CAL27
TumCG↓, Ferroptosis↑, TumCMig↓, NRF2↓, i-GSH↓, Iron↑, ROS↑,
5704- BRU,    Brusatol ameliorates psoriatic dyslipidemia by targeting IL-1β to restore AMPK-mediated lipid homeostasis
- in-vivo, PSA, HaCaT
*Inflam↓, *IL17↓, *TNF-α↓, *IL22↓, *STAT3↓, *other↝, *eff↑, *Dose?,
5703- BRU,    Brusatol Enhances the Radiosensitivity of A549 Cells by Promoting ROS Production and Enhancing DNA Damage
- in-vitro, Lung, H1299 - in-vitro, Lung, A549 - in-vitro, Lung, H460
NRF2↓, RadioS↑, DNAdam↑, ROS↑,
5702- BRU,  BJ,    Brusatol inhibits metastasis of triple-negative breast cancer through metabolic reprogramming
- in-vitro, BC, NA
AntiTum↑, PPP↓, Glycolysis↓, TCA↓, NADPH↓, ROS↑, chemoP↑, e-LDH↑, TumMeta↓, Glycolysis↓,
5701- BRU,    Brusatol induced ferroptosis in osteosarcoma cells by modulating the Keap1/Nrf2/SLC7A11 signaling pathway
- in-vitro, OS, NA
TumMeta↓, TumCP↓, ROS↑, Ferroptosis↑, NRF2↓, ChemoSen↑,
5707- Brut,    Targeting Redox Homeostasis and Cell Survival Signaling with a Flavonoid-Rich Extract of Bergamot Juice in In Vitro and In Vivo Colorectal Cancer Models
- in-vitro, CRC, HCT116
Risk↓, TumCG↓, Apoptosis↑, TumCCA↑, ROS↑, MMP↓, DNAdam↑, TumMeta↓, TumCP↓,
5706- Brut,    Bergamot juice extract inhibits proliferation by inducing apoptosis in human colon cancer cells
- in-vitro, CRC, HT29
TumCG↓, MAPK↓, TumCCA↑, Apoptosis↑, ROS↑, DNAdam↑, AntiCan↑,
5714- Brut,    Probable Interaction of Bergamottin and Cyclosporine in a Lung Transplant Recipient
- Case Report, Nor, NA
*CYP3A4↓,
5713- Brut,    Standardized bergamot polyphenolic fraction – a comprehensive dietary supplement with pleiotropic properties compared to other selected natural lipid-lowering substances available on the market
- Review, Nor, NA
*eff↑, *lipid-P↓,
5712- Brut,    The anti-inflammatory and antioxidant effects of bergamot juice extract (BJe) in an experimental model of inflammatory bowel disease
- in-vivo, IBD, NA
Diar↓, Weight↑, NF-kB↓, p‑JNK↓, ICAM-1↓,
5711- Brut,    Citrus bergamia powder: Antioxidant, antimicrobial and anti-inflammatory properties
- in-vitro, Nor, HMEC
*antiOx↑, *Bacteria↓, *GutMicro↑,
5705- Brut,    A flavonoid-rich extract from bergamot juice prevents carcinogenesis in a genetic model of colorectal cancer, the Pirc rat (F344/NTac-Apcam1137)
- in-vivo, CRC, NA
Risk↓, TumMeta↓, Apoptosis↑, COX2↓, iNOS↓, IL1β↓, IL6↓, IL10↓, P53↑, P21↓, survivin↓, chemoPv↑, *Inflam↓,
5710- Brut,    Recycling of Industrial Essential Oil Waste. Brutieridin and Melitidin, two Anticholesterolaemic Active Principles from Bergamot Albedo
- Review, Nor, NA
*other↝,
5709- Brut,    Mechanisms Underlying the Anti-Tumoral Effects of Citrus bergamia Juice
- in-vitro, neuroblastoma, SH-SY5Y
TumCG↓, TumCCA↑, FAK↓, TumCMig↓, Dose↝, NCAM↓,
5708- Brut,    Clinical application of bergamot (Citrus bergamia) for reducing high cholesterol and cardiovascular disease markers
- Review, Nor, NA
*Imm↑, *cardioP↑, *LDL↓, toxicity↓,
6549- BSB,    (-)-α-bisabolol prevents neuronal damage and memory deficits through reduction of proinflammatory markers induced by permanent focal cerebral ischemia in mice
- in-vivo, Nor, NA
*antiOx↑, Inflam↓, *Dose↝, *neuroP↑, *motorD↑, *memory↑, *MPO↓, *TNF-α↓, *iNOS↓,

Showing Research Papers: 1701 to 1750 of 7372
Prev Page 35 of 148 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7372

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Ferroptosis↑, 3,   GPx4↓, 1,   GSH↓, 1,   i-GSH↓, 1,   Iron↑, 1,   i-Iron↑, 1,   lipid-P↑, 1,   NRF2↓, 11,   ROS↓, 1,   ROS↑, 13,   ROS↝, 1,   ROS∅, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

Tf↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   MMP↓, 4,   MMP↝, 1,   p42↑, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   cMyc↓, 4,   Glycolysis↓, 3,   e-LDH↑, 1,   NADPH↓, 1,   NADPH↝, 1,   PPP↓, 1,   TCA↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 4,   p‑Akt↓, 1,   p‑Akt↑, 1,   Apoptosis↑, 10,   BAX↑, 4,   Bax:Bcl2↑, 1,   Bcl-2↓, 4,   cl‑Bcl-2↑, 1,   Bcl-xL↓, 3,   Casp↑, 2,   Casp3↑, 2,   proCasp3↑, 1,   Casp8↑, 2,   cl‑Casp8↑, 1,   Casp9↑, 1,   cl‑Casp9↑, 1,   Cyt‑c↑, 2,   Diablo↑, 1,   DR4↑, 1,   Ferroptosis↑, 3,   IAP1↓, 2,   ICAD↓, 1,   iNOS↓, 1,   JNK↑, 1,   p‑JNK↓, 1,   p‑JNK↑, 1,   MAPK↓, 1,   MAPK↑, 1,   p‑MAPK↑, 1,   p27↑, 1,   p38↑, 1,   survivin↓, 5,   TNFR 1↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

miR-27a-3p↓, 2,   PhotoS↑, 2,   sonoS↑, 1,   tumCV↓, 4,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3B↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 5,   P53↓, 1,   P53↑, 1,   cl‑PARP↑, 4,   PARP1↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 3,   cycD1/CCND1↓, 5,   cycE/CCNE↓, 1,   P21↓, 2,   P21↑, 2,   p‑RB1↓, 1,   TumCCA?, 1,   TumCCA↑, 7,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 1,   p‑ERK↑, 1,   Let-7↑, 2,   miR-34a↑, 2,   mTOR↓, 3,   NOTCH↓, 1,   PI3K↓, 2,   PTEN↑, 1,   STAT3↓, 4,   TumCG↓, 12,  

Migration(tgid=13) ⓘ

5LO↓, 4,   Ca+2↑, 1,   CD31↓, 1,   E-cadherin↑, 2,   FAK↓, 1,   Ki-67↓, 1,   miR-200b↑, 1,   MMP2↓, 1,   MMP9↓, 3,   NCAM↓, 1,   ROCK1↓, 1,   TumCI↓, 3,   TumCMig↓, 6,   TumCP↓, 9,   TumMeta↓, 6,   Vim↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   EGFR↓, 2,   HIF-1↓, 1,   Hif1a↓, 2,   NO↑, 1,   VEGF↓, 3,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 5,   CXCR4↓, 4,   ICAM-1↓, 2,   IL10↓, 1,   IL1β↓, 1,   IL6↓, 1,   Imm↑, 1,   Inflam↓, 1,   NF-kB↓, 7,   PGE2↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 10,   Dose↝, 1,   eff↑, 2,   MRP1/ABCC1↓, 1,   RadioS↑, 3,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ascitic↓, 1,   EGFR↓, 2,   HER2/EBBR2↓, 1,   IL6↓, 1,   Ki-67↓, 1,   e-LDH↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   AntiTum↑, 2,   chemoP↑, 1,   chemoPv↑, 1,   Risk↓, 2,   toxicity↓, 2,   TumVol↓, 1,   Weight↑, 1,   Weight∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

Diar↓, 1,  
Total Targets: 145

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   HO-1↑, 1,   lipid-P↓, 2,   MPO↓, 1,   NRF2↑, 1,   ROS↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

CYP3A4↓, 1,   LDL↓, 1,  

Cell Death(tgid=5) ⓘ

iNOS↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 2,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

STAT3↓, 1,  

Barriers & Transport(tgid=15) ⓘ

P-gp↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL17↓, 1,   IL22↓, 1,   Imm↑, 1,   Inflam↓, 2,   TNF-α↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   ChemoSen↑, 1,   Dose?, 1,   Dose↝, 1,   eff↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

GutMicro↑, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   memory↑, 1,   motorD↑, 1,   neuroP↑, 1,   toxicity↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 30

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page